JHN Journal
Volume 13 | Issue 1

Article 2

Winter 2018

Phase 1 Trial of Vaccination with Autologous
Tumor Cells and Antisense Directed Against the
Insulin Growth Factor Type 1 Receptor (IGF-1R
AS ODN) in Patients with Recurrent Glioblastoma
David W. Andrews MD
Thomas Jefferson University, david.andrews@jefferson.edu

Kevin Judy, MD
Thomas Jefferson University, Kevin.Judy@jefferson.edu

Larry Harshyne, PhD
Thomas Jefferson University, larry.harshynejr@jefferson.edu

D. Craig Hooper, PhD
Thomas Jefferson University, douglasc.hooper@jefferson.edu

Follow this and additional works at: https://jdc.jefferson.edu/jhnj

Let us know how access to this document benefits you
Recommended Citation
Andrews MD, David W.; Judy, MD, Kevin; Harshyne, PhD, Larry; and Hooper, PhD, D. Craig (2018) "Phase 1 Trial of Vaccination
with Autologous Tumor Cells and Antisense Directed Against the Insulin Growth Factor Type 1 Receptor (IGF-1R AS ODN) in
Patients with Recurrent Glioblastoma," JHN Journal: Vol. 13 : Iss. 1 , Article 2.
DOI: https://doi.org/10.29046/JHNJ.013.1.002
Available at: https://jdc.jefferson.edu/jhnj/vol13/iss1/2

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
JHN Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Andrews MD et al.: Phase 1 Trial of Vaccination with Autologous Tumor Cells

Recurrent Glioblastoma

Phase 1 Trial of Vaccination with Autologous
Tumor Cells and Antisense Directed Against the
Insulin Growth Factor Type 1 Receptor (IGF-1R AS
ODN) in Patients with Recurrent Glioblastoma
David W. Andrews, MD1; Kevin D. Judy, MD1; Larry A. Harshyne, PhD1;
D. Craig Hooper, PhD2
1

Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA
Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA

2

ABSTRACT
Background: Extending a previous Phase I study, we report the results of a second
Phase I autologous tumor cell vaccination trial for patients with recurrent glioblastomas
(IND 14379-101, NCT01550523).
Methods: Following surgery, subjects were treated by 24 hour implantation in the
rectus sheath of ten biodiffusion chambers containing irradiated autologous tumor cells
and IGF-1R AS ODN with the objective of stimulating tumor immunity. Patients were
monitored for safety, clinical and radiographic as well as immune responses.
Results: There were no Grade 3 toxicities related to protocol treatment and overall
median survival from initial diagnosis was 91.4 weeks. Two protocol survival cohorts
with median survivals of 48.2 and 10 weeks were identified and predicted by our
pre-treatment assessments of immune function, corroborated by post-vaccination
pro-inflammatory cytokine profiles. Longer survival subjects had imaging findings
including transient elevations in cerebral blood volume (rCBV) and sustained elevations
of apparent diffusion coefficient (ADC) interpreted as transient hyperemia and cell loss.
Conclusions: The vaccine paradigm was well-tolerated with a favorable median
survival. Our data support this as a novel treatment paradigm that promotes anti-tumor
immunity.

KEYWORDS
Decompressive Hemicraniectomy, Intracerebral Hemorrhage, Malignant MCA Stroke,
Traumatic Brain Injury, Aneurysmal Subarachnoid Hemorrhage, Intracranial Pressure,
Herniation

INTRODUCTION
WHO Grade IV astrocytoma (glioblastoma) is a uniformly fatal primary intracranial malignancy with a median survival of 14 months.1 We conducted an earlier pilot Phase I vaccine
trial in patients with high grade astrocytomas2 and designed a replacement Phase 1 trial
with optimized reagents, expanded radiographic response criteria, and new exploratory
objectives.

METHODS
Study Site and Patients
The study was conducted at Thomas Jefferson University and reached target accrual
of 12 patients in 14 months. Criteria for enrollment included age > 18, a Karnofsky
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performance score of 60 or better, and
no co-morbidities that would preclude
elective surgical re-resection. Twelve
patients were enrolled for treatment after
failure from standard therapy.1 A summary
of enrolled patients, and all available pertinent data is included in Table 1.

Study Design and Objectives
As before, the combination product
consisted of autologous tumor cells
removed at surgery then treated overnight with the IGF-1R AS ODN (4mg/ml)
prior to being added to semi-permeable
chambers and irradiated. 2 Enhancements to the vaccine product included
use of an 18-mer IGF-1R AS ODN with
the sequence 5’-TCCTCCGGAGCCAGACTT-3’, two frameshifts upstream
from the previous sequence; and, based
on data showing that the AS ODN has
immunomodulatory properties,3,4 addition of 2 mg of exogenous antisense to
the chambers (C-v). The protocol was
also amended to include an eleventh
control chamber containing PBS (C-p).
Study objectives included assessment
of safety and radiographic responses as
well as exploratory objectives looking at
immune function and response.

Radiological Assessments
Serial imaging assessments were
performed on Philips 1.5T and 3T MRIs
and GE 1.5 T MRIs. Routine anatomic MRI
features were evaluated as well as physiologic measurements including dynamic
susceptibility weighted (DSC) MR perfusion and 15-direction diffusion tensor
imaging (DTI) were also utilized.

Immunological Assessments
Plasma leukopheresis was performed
one week before surgery for baseline
assessment of immune function. Blood
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Table 1. Summary of Patients Enrolled.
Subject

Age

KPS

Interval between
surgeries (weeks)

# chambers
implanted

Original lymphocyte
count (cells/mm2)

Lymphocyte count
at enrollment
(cells/mm2)

Previous
treatments

IDH-1 mutation/
MGMT methylation

TJ01

39

70

177

10

N/A

400

S,RT + TMZ, Bev

-/

TJ02

57

80

90

9

N/A

1570

S,RT + TMZ

-/methylated

TJ03

75

70

32

7

700

300

S,RT + TMZ

-/

TJ06/R1

66

80

54

8

2000

1300

S,RT + TMZ

-/

TJ07

43

80

215

10

500

430

S, RT + TMZ,
Bev; RTOG 0525

+/

TJ08

55

80

52

8

1000

500

S,RT + TMZ

-/

TJ09

57

80

61

7

1400

300

S, RT + TMZ,
RTOG 0929

-/unmethylated

TJ10

47

60

376

7

N/A

1800

S, RT + TMZ, Bev

-/methylated

TJ11

39

70

32

11*

2400

200

S, RT + TMZ

-/

TJ12

60

80

74

7

1100

600

S, RT + TMZ,
Panobinostat

-/

TJ13

64

80

182

11

N/A

2100

S, RT + TMZ

-/

TJ14/R

77

90

30

7/11

1800

1100

S, RT + TMZ

-/unmethylated

1

Compassionate retreatment; *Protocol amendment to include control chamber filled with phosphate buffered saline; S: surgery; RT: radiation therapy;
TMZ: temozolamide chemotherapy; Bev: bevacizumab chemotherapy; IDH-1: isocitrate dehydrogenase-1

was obtained post-operatively on days
7, 14, 28, 42, 56, and every 3 months
after vaccination. Sera and cell fractions
were separated by centrifugation and
cells were treated with red blood cell
lysis buffer and white blood cells either
quantified by flow cytometry or stored
in DMSO at -80°C. Serum samples were
also stored at -80°C. Flow cytometry
was performed as previously described5
using an EasyCyte 8HT (Millipore) and
fluorescently-conjugated mAb specific
for human CD4, CD8,CD11b, CD14,
CD16, CD20, CD45, CD56, CD80, CD83,
and CD 86 (all from BD Biosciences), and
CD163 (R&D Systems). Post- collection
analysis was performed with FlowJo
software (Tree Star Inc, Ashland, OR).
Serum cytokine factors were quantified
using Luminex bead arrays (human cytokine/chemokine panels I, II, and III from
Millipore and HCMBMAG/ MILLIPLEX
Mag Cancer multiplex assay (emdmillipore.com). This included 6 serum markers
for glioma related to stem cell function
including DKK-1, NSE, Osteonectin,
Periostin, YKL-40, and TWEAK. T-cell
stimulation was performed with phorbol
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12-myristate,13 acetate (PMA) and ionomycin as previously described.6 PBMC
from glioblastoma patients and normal
donors were cultured for 24 hours at 37°C
and 5% CO2 in AIMV media containing
10% fetal bovine serum (Gibco). Nonadherent lymphocytes were transferred
to new plates in order to eliminate
non-specific effects of contaminating
monocytes. Lymphocyte cultures were
stimulated with phorbol 12-myristate
13-acetate (PMA, 100 ng/ml) and ionomycin (0.1 mM, both from Sigma-Aldrich)
for 18 hours. BD Golgiplug™ (1:1000,
Brefeldin A, BD Bioscience) was added
during the last 6 hours of culture to
permit cytokine accumulation.
Tumor tissue sections were assessed
by immunohistochemistry or immunofluorescence, adapting the method of
Emoto7, for GFAP, IGF-1R, CD163, CD14,
CD3, CD4, and CD8. Immunopositive
cells were counted quantitatively with
Aperio or qualitatively by an experienced
neuropathologist (LEK) using an ordinal
scale from 0 (no staining) to 6 (strong
diffuse staining) with staining intensity

rated as low, moderate and strong and
staining patterns described as focal or
diffuse.
Cytokine/chemokine levels in tumor cell
supernatant were analyzed by Luminex
kits as designated above. Membranes
from paired vaccine and control chambers were embedded in paraffin for
standard immunohistopathologic examination. Post-mortem autopsy was limited
to examination of the brain and findings
were compared to archival paraffin
blocks of previously treated or untreated
glioblastomas diagnosed at autopsy.

Statistical Analysis
The level of statistical significance
between quantitative measures in
different samples was determined by a
two-tailed unpaired t-test or matched
pairs t-test with p < .05. Survival analysis
was performed by Kaplan-Meier analysis
and significance established by log
rank comparisons. All statistical analysis
including mixture discriminant analysis
was performed with JMP v. 11 software
(SAS, North Carolina).
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Figure 1. Survival Metrics.
A. Overall survival of patients in trial; B. protocol survival with two survival cohorts; Nine patients died of disease progression while one died
of intracerebral hemorrhage and two of sepsis. Overall protocol survival was 48.2 weeks and 9.2 weeks, respectively for longer (N = 4) and
short (N = 8) survival cohorts (log-rank = .014). C. Excluding one outlier and three non-disease-related deaths linear regression revealed high
correlation between protocol survival and lymphocyte count at enrollment (R2 = .8, p = .0028).

RESULTS
Safety Assessment and Clinical
Course
Only one SAE was related to the protocol
(femoral vein thrombosis after leukopheresis). Nine patients succumbed to
tumor progression while three patients
died from other causes. Five autopsies
were performed.
Median overall survival from initial diagnosis was 91.4 weeks which compared
favorably to other recurrent glioma
immunotherapy trials.8-13 Two significantly different protocol survival cohorts
of 48.2 and 10 weeks were identified
as longer and short survival cohorts,
respectively (Figure 1A&B). Excluding
one outlier (TJ03), we documented a
significant correlation between protocol
survival and degree of lymphopenia at
enrollment (Figure 1C). Comparison of
CBC values at initial diagnosis and at
protocol enrollment indicated that the
mean lymphocyte count had dropped
significantly (65%) after standard therapy
(N=8, p = .012, paired t-test).

Radiographic Responses
Routine MRI features were assessed
as previously described.2 In the longer
survivors we noted diminished size
of enhancement and FLAIR envelope
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at the primary tumor site and slower
progression. Examples of anatomic
responses in both cohorts is included
noted in Figure 2A&B. Physiologic MRI
measurements augmented these anatomic
observations for both cohorts is featured
in Figure 2C&D. Sequential DSC MR perfusion was performed in 7 patients, including
3 longer-term survivors (TJ03, TJ06, and
TJ09) who had a paradoxical increase in
rCBV while improving clinically; however,
this effect was transient and there was
a more sustained decrease in rCBV.
Sequential 15 directions DTI data included
two long-term survivors (TJ03 and TJ06)
who showed ADC values increasing in the
affected hemisphere, reflecting loss of
tumor cellularity associated with disease
regression.

Immunologic Response
Assessments after Vaccination by
Survival Cohort
Levels of 24 of the 78 cytokines/chemokines assessed were significantly higher
in serum from the longer survival cohort
compared to the short cohort. A spike in
serum CCL2 occurred after surgery but
was absent at re-operation in two patients.
CCL2 levels remained significantly higher
throughout the post-operative period in
the short survival cohort. These postoperative spikes were highly correlated
with TNF-a spikes. (data not shown).

Actual CD4 and CD8 T cell counts as well
as DC counts were significantly higher in
the longer cohort compared to the short
cohort. There was a significant correlation
between CD4 and DC cells and between
CD4 and CXCL12 only in the longer
cohort. Coordinated changes between
circulating levels of T cells, monocytes,
and pro-inflammatory chemokines/cytokines after vaccination were seen in three
of four longer cohort subjects.
As a distinguishing feature differentiating
the cohorts, peripheral blood cells from
the longer survival subjects manifested
significantly higher Th-1 cytokine production including IFN-g after stimulation with
PMA and ionomycin from PBMC obtained
on day 14.
Levels of circulating lymphocytes were
significantly decreased (p<0.0001) in all
GBM patients when compared to normal
subject samples (Figure 1A, left panel) and
the medians of both patient populations
fell outside of the normal range (Figure
1A, gray lines). Patients in this same cohort
exhibited significantly higher levels of
monocytes (Figure 1A, right panel, p<0.05),
but the medians of these cell populations
fell within normal range.
The mere presence of a given cell
subset is not enough to ensure proper
immune function. The cell must also be
able to respond to stimuli and produce
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Figure 2. Radiographic responses with associated physiologic measurements and cytokine profiles.
A. Examples of short survival cohort. TJ11: A-D; TJ10: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; G: T1-gadoliniumenhanced coronal image; C: pre-operative axial FLAIR image. B,D,F,H: respective 3 month post-operative images. B. Examples of longer
survival cohort. TJ06: A-D: TJ09: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; C,F: pre-operative axial FLAIR images.
B,D,F,H: respective 3 month post-operative images. C. Relationship between relative cerebral blood volume in tumor v. apparent diffusion
coefficient in short survival cohort. D. Relationship between relative cerebral blood volume in tumor v. apparent diffusion coefficient in
longer survival cohort; there is a high correlation between the ADC and rCBV (R2 = .96, p = .0005).

appropriate immune modulators.
T-helper type 1 immunity is considered to be the appropriate anti-tumor
immune response. Cultures of nonadherent lymphocytes were stimulated
nonspecifically with phorbol 12-myristate
13-acetate (PMA) and ionomycin overnight in order to stimulate the production
of IFN-g, the prototypical Th1 cytokine
which was detected by intracellular
cytokine flow cytometry. Viable, CD3+
T cell-specific gates were established
(Figure 1B) and the median fluorescence
intensity (MFI) of IFN-g+ T cells was
normalized to T cells that did not produce
cytokine (IFN-g+ T cells). PMA/ionomycin
stimulation of normal T cells resulted in a
26-fold increase in the IFN-g MFI (Figure
1B, right panel). T cells enriched from
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patients with primary and recurrent GBM
produced significantly less IFN-g when
compared to normal controls (p< 0.01),
but there was no difference between
GBM patient cohorts (Figure 1B, right
panel).
Moreover, while a difference in the
quantity of IFN-g produced by the T cells
was observed, there was no difference in
the frequency of IFN-g+ T cells between
these two cohorts (data not shown). In
order to assess the relationship between
lymphocyte numbers and immune functional capacity, we performed linear
regression analyses. Lower levels of
circulating lymphocytes are associated
with a statistically significant (R2=0.508,
p=0.0093) decrease in IFN-g production
following PMA/ionomycin stimulation

(Figure 1C, left panel). Furthermore,
recursive partitioning analyses identified
two different populations (R2=0.547) of
recurrent GBM patients enrolled in our
clinical trial (Figure 1C, right panel).
Reanalyzing these data focusing on
single parameters based on the functional immune capacity confirmed the
highly significant differences identified
by recursive partitioning (Supplementary
Figure 1). Patients with higher immune
function possessed 3-fold higher levels of
lymphocytes (p<0.0001) and half as many
monocytes (p<0.005) when compared to
the lower functioning group (Supplementary Figure 1). In addition to higher levels
of lymphocytes, the T cells from patients
with higher immune function produced
twice as much IFN-g following stimulation
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A. Lymphocyte and monocyte frequencies are expressed as a percentage of white blood cells as determined by clinical blood counts
performed by Thomas Jefferson University Hospital. Frequencies in trial patients are compared to primary glioblastoma patients and
normal blood donors. Scatter dot plots indicate the mean frequency and standard deviation. Statistical significance of differences between
tumor patients and normal blood donors were assessed by ANOVA followed by Dunnett’s post-test (****p<0.0001 and *p<0.05). Gray
lines represent the upper and lower range of normal values. GBM signifies newly diagnosed patients; GBMr signifies recurrent glioblastoma
patients. B. Non-adherent peripheral blood mononuclear cells were stimulated with PMA/ionomycin and cytokine production was assessed
by intracellular flow cytometry. Live cell gates were established in forward- and side-scatter plots (left panel). Quadrant gates were used
to assess IFN-g production in CD3+ T lymphocytes (middle panel). Numbers indicate the frequency of cells in a given quadrant. Median
fluorescence intensity of IFN-g +CD3+ cells was normalized to IFN-g -CD3+ cells and is presented as a ratio in scatter dot plots (right panel).
Statistical significance of the difference between tumor patients and normal blood donors was assessed by ANOVA followed by Dunnett’s
post-test (***p<0.0005). C. Left panel: Recursive partitioning analysis separated the trial patients into groups with higher and lower
immune functional capacity (R2=0.547). Right panel pair: Linear regression analysis of IFNg production versus peripheral blood lymphocyte
frequency revealed a significant association of these variables only in the longer survival cohort with a positive correlation (R2=0.83).
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with PMA/ionomycin (Supplementary
Figure 1, p<0.01). Subsequent analyses
will focus on patients with higher/lower
functional immune capacity. Analysis of
hospital-acquired blood cell counts fail
to take in to consideration immune cell
subsets. We performed flow cytometry
phenotyping in order to further characterize the white blood cells. Frequencies
of CD20+ B cells were significantly
decreased in those patients with lower
cohort (p<0.005) and fell outside of the
normal average (Figure 2). CD4+ T cells
in both cohorts were significantly lower
than the normal average, while CD14+
monocytes were significantly increased
compared to normal averages (Figure 2) in
both partitioned cohorts. CD8+ T cells in
both cohorts were similar to normal averages (Figure 2). There was no difference
between the lower and higher cohorts
with respect to CD4+ or CD8+ T cell, or
CD14+ monocyte frequencies (Figure 2).

DISCUSSION
Like its predecessor, the revised
autologous cell/chamber-based GBM
vaccination trial did not raise any significant safety concerns. We recognized,
however, that an immunotherapy trial
for recurrent GBM faces incumbent challenges. Patients emerging from standard
therapy for GBM often have severe leukopenia,14 which was also documented in
the current trial. It was therefore not
surprising that we could not document T cell infiltrates in the TME after
treatment. Surgery itself enhances host
immune mechanisms favoring tumor
growth through the attraction of M2
macrophages to the tumor environment
postoperatively15,16 suggested by the CCL2
serum spike provoked by craniotomy.
Other than this post-operative serum
spike, the highest levels of CCL2 expression were found in the tumor supernatants
during vaccine preparation supporting
well-documented observations that CCL2
is produced from cells in the TME.17,18 The
lack of a CCL2 peak after re-vaccination in
two patients suggested loss of these cells
after the first vaccination.
We identified two significantly different
survival cohorts with different responses
to this vaccine paradigm allowing us to
explore the nature of potentially therapeutic immune mechanisms. Serum from
the longer cohort subjects contained
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higher levels of tumor-specific antibody
isotypes and cytokines/chemokines
commonly associated with Th1 immunity including IgG1, IgG3, IL12, CXCL10,
CXCL12, CCL7, CCL19, and CCL21 not
seen in the short cohort.
The short survival cohort had longer
overall survival perhaps in part due to
MGMT methylation and better responses
to temozolamide in three patients.
However the treatment-induced lymphopenia and the lower CD4:CD8 ratio could
perhaps also be ascribed to temozolamide. Also, elevated serum CCL2 levels
found in the short cohort have been
associated with the mesenchymal gene
expression profile19 and a poor prognosis20 in glioma patients.
Cytokine production is a hallmark feature
of immune function in lymphocytes. We
used phorbol ester-mediated, non-specific
stimulation of patient lymphocytes in order
to stimulate maximal cytokine output as a
surrogate indicator of immune function.
IFN-g is the classical Th1 cytokine and the
logical choice for assessing immune fitness
of T lymphocytes in our GBM patients.
The amount of IFN-g production by T
cells following overnight stimulation was
approximately half the amount produced
by normal donor cells treated similarly.
IFN-g production and lymphocyte counts
were strongly associated and predictively
identified patients with different levels of
immune fitness that fell into either the
longer or short survival cohort. Lymphocytes from patients with higher functional
immune capacity were more frequent
and produced higher levels of IFN-g that
approached levels to those produced by
normal lymphocytes stimulated under
similar conditions. In contrast, T cells from
trial patients in the lower immune function cohort were less in number (50%) and
unable to respond to PMA stimulation.
The implanted chambers have inherent
adjuvanticity. We have confirmed that the
antisense sequence, its CpG motif, and
the direct mixture with glioma cells in situ
effectively initiate anti-tumor immunity3
also noted by others.21,22 The CpG motif
specifically interacts with TLR94 causing
plasmacytoid DC activation, measured
by CD80 and CD86 expression.5 The
elevated CD4:CD8 ratio after vaccination
in the longer survival cohort could reflect
local TLR9 DC activation and CD4 T cell
stimulation.

Evolution of resistance to treatments in
gliomas has now been associated with
activation of the IGF-1R signaling axis
and IGF-1R inhibition through a small
molecule inhibitor overcomes this resistance with improved outcomes.23 We
are currently exploring the impact of the
IGF-1 bioregulatory system in recurrent
gliomas and the impact of the IGF-1R AS
ODN in this vaccination paradigm.
Differences in the radiographic observations between the longer and short
survival patient cohorts provide further
support for the concept that the vaccination paradigm may have an impact on
the glioma TME. Higher rCBV values are
typically associated with tumor progression,24 and MR perfusion had only
transient increases in the longer cohort,
a finding not previously described. ADC
measurements differentiated tumor
progression (lower values) from what we
interpreted as cell loss (higher values).25
In summary, we have established the
safety profile of an improved combination glioma vaccine product and have
documented alterations in immune
parameters associated with clinical and
radiographic improvements. Despite
immune compromise, we documented
favorable immune responses associated
with tumor regression and longer survival
after treatment. To be most effective,
however, a replacement trial should
include screens for immune compromise
and means by which immune function
could be restored prior to vaccination.

Study Oversight
The physician sponsor (DWA) was
primarily responsible for the design
and funding of the study. All authors
participated in the conduct of the study,
analysis of the data and the reporting of
the results. After IRB approval, this study
was overseen by an independent data
safety and monitoring board appointed
by the Sidney Kimmel Cancer Center at
Thomas Jefferson University.
DWA and DCH have financial interests in
the Imvax Corporation related to this work.
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